

Ongoing: Construction continues on expansion of lab facilities.

October 2007: Dr. Fujii invited to speak at the Western Regional Meeting of the ACS.

July 2007: NIAID grant to evaluate selected Aspergillus antigens as potential candidates for vaccine development pending.

July 2007: Presentation of HSV2 findings at the 2007 American Society of Virology Annual Meeting.

July 2007: NCI grant to explore feasibility of commercial manufacturing methods for breast cancer therapeutic funded. July 2007: Dr. Fujii invited to share status of current projects with BARDA.

2001

- * Registered Trademark for VesiVax in November.
- * Phase I SBIR grant awarded for developing a targeted leukemia delivery system in August.
- * Phase I STTR grant awarded to provide anticancer formulations through a subcontract with a biotechnology company in July.
- * SCORE grant awarded in collaboration with the California State Polytechnic University Pomona for continuing the development of the HSV-2 vaccine technology.
- * Vaccine presentations of "Protection in Mice against Intravaginal Challenged with Herpes Simplex Virus Type 2 (HSV2) Associated with Novel Liposomal gD Vaccine (LDVac)" and "Efficacy of P6 Liposomal Vaccine Compared to Inactivated NTHi Mixed with Different Adjuvants in Non-Typeable Haemophilus influenzae (NTHi) Challenged Weanling Rats" at the General Meeting of the American Society of Microbiology in Orlando, Florida in May.
- * Invited to give Oral presentations of "Long Term Effects of a Novel Liposomal gD Vaccine on Minimizing Intravaginal herpes Simplex Virus Infections in Mice", "Improved Efficacy of a Herpes Simplex Virus gD Vaccine Following Incorporation of Viral Epitope and Adjuvant in Liposomes" and a poster presentation abstract of "Efficacy of Varying P6 Liposomal Vaccine Compared to Inactivated NTHi in Non-Typeable Haemophilus influenzae (NTHi) Challenged Weanling Rats" at the 4th annual Vaccine Research Conference in Arlington, Virginia in April.

2000

- * Winner of a California Technology Investment Partnership (CaTIP) award in September

(\$50,000) as one of the top innovative technology companies in the state.

- * California Breast Cancer Research Program grant awarded in collaboration with USC in July.

- * Phase I SBIR grant awarded for utilizing Molecular GPS to target cancer cells a targeted liposome system in April.

- * In April, presented at the Liposome Research Days Conference " Efficacy of Liposomal Herpes Simplex Virus Type 2 (HSV-2) gD Vaccine (IgDVac) in Murine HSV-2 Intravaginal and Systemic Models".

1999

- * Patent application covering the vaccine technology filed in September.

- * Winner of a California Technology Investment Partnership (CaTIP) award in August (\$150,000) as one of the top innovative technology companies in the state.

- * Phase I SBIR grant awarded for developing an Influenza vaccine in March.

1998

- * Presentation of the initial vaccine results at the 38th annual Interscience Conference on Antimicrobial Agents and Chemotherapy in September.

- * Phase I SBIR grant awarded for developing an HIV vaccine in August.

- * Phase I SBIR grant awarded for developing an HSV2 vaccine in June.

1996

- * Molecular Express founded in April